By Maddy Hunter, Program Associate, CCC
An important role of the Computing Community Consortium (CCC) is responding to government requests for information. The CCC does this by recruiting various members of the computing research community to synthesize main points and incorporate a variety of opinions into a response. In the past couple of months alone, the CCC has responded to five requests. The responses are highlighted below:
In May 2023, the President’s Council of Advisors on Science and Technology (PCAST) published a Request for Public Input to help assess key opportunities and risks and provide input on how best to ensure that these GenAI technologies are developed and deployed as equitably, responsibly, and safely as possible. You can read the response here.
In April 2023, the National Science Foundation published a Request for Information to inform the development of a roadmap for the recently established Technology, Innovations, and Partnerships (TIP) Directorate. This roadmap will help to determine the areas of use-inspired translational research and projects which the TIP directorate will fund, with a goal to advance US competitiveness in the key technology areas identified within the Request for Information. The Computing Research Association’s (CRA) Computing Community Consortium (CCC) and CRA’s Government Affairs Committee (GAC) drafted a joint response. You can read the full response here.
In May 2023, the Office of Science and Technology Policy (OSTP) published a request for information to inform the development of the Biden-Harris Administration’s National Artificial Intelligence (AI) Strategy. The strategy will chart a path for the United States to harness the benefits and mitigate the risks of AI building on the actions that the Federal Government have already taken to responsibly advance the development and use of AI. Public comments will help to update U.S. national priorities and future actions on AI. You can read the response here.
In May 2023, the Food and Drug Administration (FDA) announced the release of a discussion paper named “Using Artificial Intelligence and Machine Learning in the Development of Drug and Biological Products” and published a request for comment. The FDA’s Center for Drug Evaluation and Research (CDER), worked with the Center for Biologics Evaluation and Research (CBER) and Center for Devices and Radiological Health (CDRH), including the Digital Health Center of Excellence (DHCoE), on the paper and attached discussion questions. Their goal is to initiate a conversation with stakeholders on the use of AI and ML to help inform the drug development regulatory landscape. You can read the full response here.
In June 2023, the National Telecommunications and Information Administration (NTIA) sought comments on Artificial Intelligence (“AI”) system accountability measures and policies. This request focuses on self-regulatory, regulatory, and other measures and policies that are designed to provide reliable evidence to external stakeholders—that is, to provide assurance—that AI systems are legal, effective, ethical, safe, and otherwise trustworthy. NTIA will rely on these comments, along with other public engagements on this topic, to draft and issue a report on AI accountability policy development, focusing especially on the AI assurance ecosystem. You can read the full response here.
You can read past CCC responses on the CCC website as well as keep up with new responses.